Company intelligence / Profile preview

CorWave

Clichy, Île-de-France, Francecorwave.com ↗

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

CorWave has completed successful long-term preclinical studies of its novel wave membrane LVAD, demonstrating six months of continuous operation in animal models with no device failures or thrombosis and without chronic anticoagulation. The results show strong hemocompatibility and pave the way for First-In-Human clinical trials expected to begin soon.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically implantable cardiac assist device / LVAD)
Industry: Implantable Medical Devices

Partnerships

Supported by Sofinnova Partners and MD Start; no major pharma/biotech partnerships disclosed as of June 2025

Beyond the preview

Go deeper on CorWave.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorWave.

Explore the full profile